Does the media prefer IRWD or ABBV?

In the previous week, AbbVie had 51 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 54 mentions for AbbVie and 3 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.08 beat Ironwood Pharmaceuticals' score of 0.54 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 35 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Positive

Does the media favor IRWD or ZLAB?

In the previous week, Ironwood Pharmaceuticals had 1 more articles in the media than Zai Lab. MarketBeat recorded 3 mentions for Ironwood Pharmaceuticals and 2 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.74 beat Ironwood Pharmaceuticals' score of 0.54 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRIX or IRWD?

In the previous week, Nurix Therapeutics had 3 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 6 mentions for Nurix Therapeutics and 3 mentions for Ironwood Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 1.11 beat Ironwood Pharmaceuticals' score of 0.54 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IRWD or BEAM?

In the previous week, Beam Therapeutics had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 4 mentions for Beam Therapeutics and 3 mentions for Ironwood Pharmaceuticals. Beam Therapeutics' average media sentiment score of 1.16 beat Ironwood Pharmaceuticals' score of 0.54 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SLS or IRWD?

In the previous week, SELLAS Life Sciences Group had 7 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 3 mentions for Ironwood Pharmaceuticals. SELLAS Life Sciences Group's average media sentiment score of 0.60 beat Ironwood Pharmaceuticals' score of 0.54 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ironwood Pharmaceuticals (IRWD) Competitors

$4.13 -0.16 (-3.73%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$4.16 +0.04 (+0.85%)

As of 08/24/2026 06:42 PM Eastern

Compare

IRWD vs. ABBV, ZLAB, NRIX, BEAM, and SLS

Should you buy Ironwood Pharmaceuticals stock or one of its competitors? Ironwood Pharmaceuticals's main competitors and comparable companies include AbbVie (ABBV), Zai Lab (ZLAB), Nurix Therapeutics (NRIX), Beam Therapeutics (BEAM), and SELLAS Life Sciences Group (SLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ironwood Pharmaceuticals compare to AbbVie?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Ironwood Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

70.2% of AbbVie shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.30	$24.02M	$0.77	5.36
AbbVie	$61.16B	7.64	$4.23B	$3.54	74.75

Ironwood Pharmaceuticals currently has a consensus price target of $6.23, indicating a potential upside of 50.93%. AbbVie has a consensus price target of $275.95, indicating a potential upside of 4.29%. Given Ironwood Pharmaceuticals' higher probable upside, research analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Ironwood Pharmaceuticals has a net margin of 33.36% compared to AbbVie's net margin of 9.80%. Ironwood Pharmaceuticals' return on equity of -58.38% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
AbbVie	9.80%	-422.07%	14.34%

In the previous week, AbbVie had 51 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 54 mentions for AbbVie and 3 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.08 beat Ironwood Pharmaceuticals' score of 0.54 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	35 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Positive

Summary

AbbVie beats Ironwood Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Zai Lab?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Ironwood Pharmaceuticals presently has a consensus target price of $6.23, indicating a potential upside of 50.93%. Zai Lab has a consensus target price of $37.25, indicating a potential upside of 45.28%. Given Ironwood Pharmaceuticals' higher probable upside, equities research analysts plainly believe Ironwood Pharmaceuticals is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Ironwood Pharmaceuticals has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.30	$24.02M	$0.77	5.36
Zai Lab	$460.16M	6.34	-$175.54M	-$1.71	N/A

41.7% of Zai Lab shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Ironwood Pharmaceuticals had 1 more articles in the media than Zai Lab. MarketBeat recorded 3 mentions for Ironwood Pharmaceuticals and 2 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.74 beat Ironwood Pharmaceuticals' score of 0.54 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
Zai Lab	-41.86%	-27.43%	-16.72%

Summary

Ironwood Pharmaceuticals and Zai Lab tied by winning 8 of the 16 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Nurix Therapeutics presently has a consensus price target of $34.21, suggesting a potential upside of 30.24%. Ironwood Pharmaceuticals has a consensus price target of $6.23, suggesting a potential upside of 50.93%. Given Ironwood Pharmaceuticals' higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Nurix Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

In the previous week, Nurix Therapeutics had 3 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 6 mentions for Nurix Therapeutics and 3 mentions for Ironwood Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 1.11 beat Ironwood Pharmaceuticals' score of 0.54 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Nurix Therapeutics' net margin of -928.44%. Ironwood Pharmaceuticals' return on equity of -58.38% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

Ironwood Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	32.46	-$264.46M	-$3.45	N/A
Ironwood Pharmaceuticals	$296.15M	2.30	$24.02M	$0.77	5.36

Summary

Ironwood Pharmaceuticals beats Nurix Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Beam Therapeutics?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market.

Ironwood Pharmaceuticals has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.30	$24.02M	$0.77	5.36
Beam Therapeutics	$139.74M	20.94	-$79.99M	-$0.86	N/A

99.7% of Beam Therapeutics shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, indicating a potential upside of 50.93%. Beam Therapeutics has a consensus price target of $49.00, indicating a potential upside of 72.96%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Beam Therapeutics had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 4 mentions for Beam Therapeutics and 3 mentions for Ironwood Pharmaceuticals. Beam Therapeutics' average media sentiment score of 1.16 beat Ironwood Pharmaceuticals' score of 0.54 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Ironwood Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

SELLAS Life Sciences Group has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 30.17%. Ironwood Pharmaceuticals has a consensus target price of $6.23, suggesting a potential upside of 50.93%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Ironwood Pharmaceuticals has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Ironwood Pharmaceuticals	$296.15M	2.30	$24.02M	$0.77	5.36

In the previous week, SELLAS Life Sciences Group had 7 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 3 mentions for Ironwood Pharmaceuticals. SELLAS Life Sciences Group's average media sentiment score of 0.60 beat Ironwood Pharmaceuticals' score of 0.54 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to SELLAS Life Sciences Group's net margin of 0.00%. SELLAS Life Sciences Group's return on equity of -35.91% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

Summary

Ironwood Pharmaceuticals beats SELLAS Life Sciences Group on 10 of the 15 factors compared between the two stocks.

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRWD vs. The Competition

Export

Metric	Ironwood Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$708.88M	$4.01B	$7.36B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	5.36	11.69	270.56	24.05
Price / Sales	2.30	1,415.32	639.68	105.23
Price / Cash	16.67	44.94	29.03	36.89
Price / Book	-2.57	17.26	11.18	6.40
Net Income	$24.02M	-$22.72M	$3.46B	$347.95M
7 Day Performance	-4.18%	2.51%	1.73%	1.49%
1 Month Performance	11.32%	9.80%	7.33%	5.15%
1 Year Performance	225.20%	57.43%	26.11%	17.01%

Ironwood Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRWD Ironwood Pharmaceuticals	2.6917 of 5 stars	$4.13 -3.7%	$6.23 +50.9%	+225.2%	$708.88M	$296.15M	5.36	220	Analyst Upgrade
ABBV AbbVie	4.6539 of 5 stars	$256.18 +2.3%	$275.73 +7.6%	+25.8%	$450.22B	$61.16B	71.98	57,000	Positive News
ZLAB Zai Lab	2.3963 of 5 stars	$25.19 -1.8%	$40.20 +59.6%	-26.8%	$2.84B	$460.16M	N/A	1,784	Gap Down
NRIX Nurix Therapeutics	3.1193 of 5 stars	$26.93 -0.9%	$34.21 +27.0%	+159.1%	$2.80B	$36.77M	N/A	300	Positive News
BEAM Beam Therapeutics	2.1458 of 5 stars	$26.64 -1.7%	$49.00 +83.9%	+70.3%	$2.74B	$156.04M	N/A	510	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRWD) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, ZLAB, NRIX, BEAM, and SLS

How does Ironwood Pharmaceuticals compare to AbbVie?

Summary

How does Ironwood Pharmaceuticals compare to Zai Lab?

Summary

How does Ironwood Pharmaceuticals compare to Nurix Therapeutics?

Summary

How does Ironwood Pharmaceuticals compare to Beam Therapeutics?

Summary

How does Ironwood Pharmaceuticals compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, ZLAB, NRIX, BEAM, and SLS

How does Ironwood Pharmaceuticals compare to AbbVie?

Which has more volatility and risk, IRWD or ABBV?

Do institutionals & insiders believe in IRWD or ABBV?

Which has stronger earnings & valuation, IRWD or ABBV?

Do analysts recommend IRWD or ABBV?

Is IRWD or ABBV more profitable?

Does the media prefer IRWD or ABBV?

Summary

How does Ironwood Pharmaceuticals compare to Zai Lab?

Do analysts recommend IRWD or ZLAB?

Which has more volatility and risk, IRWD or ZLAB?

Which has preferable valuation and earnings, IRWD or ZLAB?

Do insiders & institutionals believe in IRWD or ZLAB?

Does the media favor IRWD or ZLAB?

Is IRWD or ZLAB more profitable?

Summary

How does Ironwood Pharmaceuticals compare to Nurix Therapeutics?

Do analysts rate NRIX or IRWD?

Which has more risk & volatility, NRIX or IRWD?

Does the media prefer NRIX or IRWD?

Is NRIX or IRWD more profitable?

Which has preferable earnings and valuation, NRIX or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to Beam Therapeutics?

Which has more risk & volatility, IRWD or BEAM?

Which has preferable earnings & valuation, IRWD or BEAM?

Do institutionals & insiders believe in IRWD or BEAM?

Is IRWD or BEAM more profitable?

Do analysts rate IRWD or BEAM?

Does the media refer more to IRWD or BEAM?

Summary

How does Ironwood Pharmaceuticals compare to SELLAS Life Sciences Group?

Which has more risk and volatility, SLS or IRWD?

Do analysts recommend SLS or IRWD?

Which has higher valuation and earnings, SLS or IRWD?

Does the media refer more to SLS or IRWD?

Do insiders and institutionals have more ownership in SLS or IRWD?

Is SLS or IRWD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools